Stifel Nicolaus reiterated their buy rating on shares of Amryt Pharma PLC (LON:AMYT) in a research note released on Monday morning. The firm currently has a GBX 49 ($0.61) price objective on the stock.
Separately, Beaufort Securities restated a speculative buy rating on shares of Amryt Pharma PLC in a research report on Monday, December 5th.
Amryt Pharma PLC (LON:AMYT) traded down 4.939% during mid-day trading on Monday, reaching GBX 17.111. 123,274 shares of the company’s stock traded hands. The firm’s market cap is GBX 35.65 million. Amryt Pharma PLC has a one year low of GBX 13.44 and a one year high of GBX 31.20. The firm’s 50-day moving average price is GBX 19.08 and its 200 day moving average price is GBX 17.54.
About Amryt Pharma PLC
Amryt Pharma plc, formerly Fastnet Equity plc, is a United Kingdom-based specialty pharmaceutical company. The Company focuses on developing and delivering treatments for patients with rare and orphan diseases. The Company’s products include Episalvan and Imlan. The Company’s products focus on developing somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases, including acromegaly and Cushing’s disease.